Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01568632 | Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Nov 21, 2012 | clinicaltrials |
| NCT00972101 | Infusion of Expanded Cord Blood T Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 11, 2012 | clinicaltrials |
| NCT00939172 |
| TTP607 in Refractory Solid Malignancies |
| withdrawn |
| Phase 1 |
| 0 |
| M.D. Anderson Cancer CenterOTHER |
| 0 |
| Jul 31, 2012 |
| clinicaltrials |
| NCT01139359 | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | withdrawn | Phase 1 | 0 | Alaunos TherapeuticsINDUSTRY | 0 | Jul 19, 2012 | clinicaltrials |
| NCT00886496 | Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia | withdrawn | Phase 1 | 0 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 20, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT01194193 | Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours | withdrawn | Phase 1 | 63 | AstraZenecaINDUSTRY | 0 | May 16, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00538096 | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma | withdrawn | Phase 1 | 18 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2012source: clinicaltrials